• Enzyvant receives FDA designation for investigational therapy europeanpharmaceuticalreview
    April 20, 2017
    The US Food and Drug Administration (FDA) has granted Enzyvant’s RVT-802, an investigational tissue-based therapy for the treatment of complete DiGeorge Syndrome (cDGS), breakthrough therapy designation as well as regenerative medicine advanced therapy (R
PharmaSources Customer Service